Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
Nasdaq

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

SAN FRANCISCO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Forbes

Your Guide To The Federal Work-Study Program

Have a question for Kiah Treece or our other editors? Ask here for a chance to be featured in a story. Submit your question This form is protected by reCAPTCHA ...